Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (RevlimidÂ®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer